North America Colorectal Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
USD
1,625.27 Million
USD
3,192.46 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,625.27 Million |
 Market Size (Forecast Year) |
USD 3,192.46 Million |
 CAGR |
% |
| Major Markets Players |
北美结直肠癌诊断，按产品类型（仪器和消耗品及配件）、测试类型（粪便检查、血液测试、影像学测试、肿瘤标志物、活检等）、癌症分期（0 期、I 期、II 期、III 期和 IV 期）、癌症类型（腺癌、结直肠淋巴瘤、胃肠道间质瘤、类癌瘤等）、年龄组（老年、成人和儿童）、最终用户（医院、诊断中心、癌症研究中心、门诊手术中心、学术机构等）行业趋势和预测到 2030 年。
北美结直肠癌诊断市场分析与洞察
北美对结直肠癌的认识不断提高，增强了市场需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者专注于各种服务的推出和批准。此外，诊断过程和技术的改进也促进了结直肠癌诊断测试需求的增加。
北美结直肠癌诊断市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 8.8% 的复合年增长率增长，预计到 2030 年将从 2022 年的 16.2527 亿美元达到 31.9246 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2020-2016) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品类型（仪器和消耗品及配件）、测试类型（粪便检查、血液测试、影像学测试、肿瘤标志物、活检等）、癌症分期（0 期、I 期、II 期、III 期和 IV 期）、癌症类型（腺癌、结直肠淋巴瘤、胃肠道间质瘤、类癌瘤等）、年龄组（老年、成人和儿童）、最终用户（医院、诊断中心、癌症研究中心、门诊手术中心、学术机构等）。 |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd、Koninklijke Philips NV、Thermo Fisher Scientific Inc.、Illumina, Inc.、Quest Diagnostics Incorporated、CANON MEDICAL SYSTEMS CORPORATION.、Bio-Rad Laboratories, Inc.、Merck KGaA、、FUJIFILM Corporation、Agilent Technologies, Inc.、BD、Siemens Healthcare GmbH、Neusoft Corporation、BioFire Diagnostics、Myriad Genetics Inc.、QIAGEN、Hologic, Inc.、Time Medical Holding.、FONAR Corp.、PlexBio、MinFound Medical Systems Co., Ltd、FONAR, Corp.
|
北美结直肠癌诊断市场的市场定义
结直肠癌起源于结肠或直肠。根据起源部位，这些癌症也可以称为结肠癌或直肠癌。结肠癌和直肠癌通常被归为一类，因为它们具有许多共同特征。结直肠癌是一种结肠或直肠细胞失控生长的疾病。有时它被称为结肠癌，简称结肠癌。结肠是大肠或大肠。直肠是连接结肠和肛门的通道。
有时结肠或直肠内会形成异常生长物（称为息肉）。随着时间的推移，一些息肉可能会变成癌症。筛查测试可以发现息肉，以便在变成癌症之前将其切除。筛查还有助于尽早发现结直肠癌，此时治疗效果最好。
北美结直肠癌诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
-
结直肠癌发病率不断上升
结直肠癌有时也被称为结肠癌，这个术语结合了结肠癌和直肠癌，直肠癌始于直肠。结肠癌通常影响老年人，但可能发生在任何年龄。它通常始于结肠内形成的小块非癌性（良性）细胞，称为息肉。随着时间的推移，其中一些息肉可能会变成结肠癌。
2022年，根据美国癌症协会（ACS）的出版物，2023年美国结直肠癌新发病例数为106,970例结肠癌新发病例、46,050例直肠癌新发病例，总体而言，男性一生中患结直肠癌的风险约为1/23，女性一生中患结直肠癌的风险约为1/26。
-
罹患憩室炎和溃疡性结肠炎的患者数量增加。
憩室炎是指憩室发炎，憩室是结肠内壁形成的小囊。溃疡性结肠炎 (UC) 是一种炎症性肠病(IBD)，患者的大肠内壁会出现炎症和溃疡。治疗方法包括抗生素、暂时的清流质饮食、止痛药，以及手术切除部分结肠（仅适用于少数病例）。
2022 年 6 月，根据美国国家生物技术信息中心 (NCBI) 提供的信息，溃疡性结肠炎的发病率为每年每 100,000 人 9 至 20 例。其患病率为每年每 100,000 人 156 至 291 例。溃疡性结肠炎的发病率呈双峰模式。主要发病高峰在 15 至 30 岁之间。第二个较小的发病高峰发生在 50 至 70 岁之间。
机会
-
癌症诊断和治疗的医疗支出增加
随着各国人民的可支配收入不断增加，全球医疗支出也随之增加。此外，政府机构和医疗机构正采取主动行动，加快医疗支出以满足人口需求。医疗支出的增加同时有助于医疗机构改善其结肠直肠癌诊断治疗设施，因为近年来结肠直肠癌的发病率很高。
此外，主要市场参与者采取的战略举措将为 2023-2030 年预测期内的结直肠癌诊断市场提供结构完整性和未来机会。
克制/挑战
- 成本增加、安全和便利问题
结肠直肠癌是致命的，这种癌症的诊断过程也存在安全问题。它也不划算。北美治疗费用最高的疾病之一是癌症。癌症患者可能住院并接受各种治疗，如手术、放射治疗和各种全身治疗。癌症患者的健康保险费现在比过去更贵。此外，他们的自付额、免赔额和共同保险费用也在上升。
COVID-19 对结直肠癌诊断市场的影响
COVID-19 对市场产生了积极影响。疫情期间的封锁和隔离使疾病管理和药物依从性变得复杂。因此，世界人口中各种治疗药物的使用量大幅增加。因此，疫情对这个市场产生了积极影响。
最新动态
- 2022 年 8 月，Bio-Rad Laboratories Inc. 完成了对 Curiosity Diagnostics 的收购，后者是一家总部位于波兰的医疗诊断和医疗保健市场创新技术解决方案开发商。此举帮助该公司扩大了其产品组合和北美市场占有率。
- 2022 年 1 月，QIAGEN 宣布为其超灵敏数字 PCR (dPCR) 平台 QIAcuity 不断增加的应用增加了新内容，该平台使用所谓的纳米板在两小时内处理样品（而不是其他系统所需的五小时），从而树立了新标准。这帮助该公司扩大了其在市场上的产品组合，并帮助该公司增加了整体收入。
北美结直肠癌诊断市场范围
北美结直肠癌诊断市场细分为产品类型、检测类型、癌症类型、癌症分期、年龄组和最终用户。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品类型
- 仪器
- 耗材及配件
根据产品类型，北美结直肠癌诊断市场分为仪器、消耗品和配件。
测试类型
- 影像检查
- 粪便检查
- 肿瘤标志物
- 活检
- 验血
- 其他的
根据测试类型，北美结直肠癌诊断市场分为粪便检查、影像学测试、活检、血液测试、肿瘤标志物等。
癌症类型
- 腺癌
- 结直肠淋巴瘤
- 胃肠道间质瘤
- 类癌肿瘤
- 其他的
根据癌症类型，北美结直肠癌诊断市场分为腺癌、结直肠淋巴瘤、胃肠道间质瘤、类癌瘤等。
癌症分期
- 第 0 阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
根据癌症分期，北美结直肠癌诊断市场分为 0 期、I 期、II 期、III 期和 IV 期。
年龄组
- 老年
- 成年人
- 儿科
根据年龄组，北美结直肠癌诊断市场分为老年人、成年人和儿童。
最终用户
- 医院
- 诊断中心
- 癌症研究中心，
- 门诊手术中心，
- 学术机构
- 其他的
根据最终用户，北美结直肠癌诊断市场分为医院、诊断中心、癌症研究中心、门诊手术中心、学术机构和其他。
北美结直肠癌诊断市场区域分析/见解
对结直肠癌诊断市场进行了分析，并按国家、产品类型、测试类型、癌症类型、癌症阶段、年龄组和最终用户提供了市场规模洞察和趋势，如上所述。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
在市场份额和收入方面，美国在北美结直肠癌诊断市场占据主导地位，并将在预测期内继续保持主导地位。这是由于该地区结直肠癌发病率高，且快速的研究发展正在推动市场发展。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场法规变化。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和结直肠癌诊断市场份额分析
结直肠癌诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上数据点仅与专注于结直肠癌诊断市场的公司有关。
结直肠癌诊断市场的一些主要参与者包括 F. Hoffmann-La Roche Ltd、Koninklijke Philips NV、Thermo Fisher Scientific Inc.、Illumina, Inc.、Quest Diagnostics Incorporated、CANON MEDICAL SYSTEMS CORPORATION.、Bio-Rad Laboratories, Inc.、Merck KGaA,、FUJIFILM Corporation、Agilent Technologies, Inc.、BD、Siemens Healthcare GmbH、Neusoft Corporation、BioFire Diagnostics、Myriad Genetics Inc.、QIAGEN、Hologic, Inc.、Time Medical Holding.、FONAR Corp.、PlexBio、MinFound Medical Systems Co., Ltd、FONAR, Corp.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS:
6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS
6.1 REGULATORY SCENARIO IN THE U.S
6.2 REGULATORY SCENARIO IN AUSTRALIA
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS.
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY POLICIES
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS.
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 PATHOLOGY-BASED INSTRUMENTS
8.2.1.1 PCR INSTRUMENTS
8.2.1.2 SLIDE STAINING SYSTEMS
8.2.1.3 TISSUE PROCESSING SYSTEMS
8.2.1.4 CELL PROCESSORS
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.2 IMAGING INSTRUMENTS
8.2.2.1 ULTRASOUND SYSTEMS
8.2.2.2 CT SYSTEMS
8.2.2.3 MRI SYSTEMS
8.2.2.4 OTHERS
8.2.3 BIOPSY INSTRUMENTS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 OTHER CONSUMABLES
9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 STOOL EXAMINATION
9.3 BLOOD TEST
9.3.1 COMPLETE BLOOD COUNT (CBC)
9.3.2 TUMOR MARKER TEST
9.3.3 LIVER ENZYME BLOOD TEST
9.4 IMAGING TEST
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.4.2 MRI
9.4.3 ULTRASOUND
9.4.4 POSITION EMISSION TOMOGRAPHY (PET)
9.4.5 OTHERS
9.5 TUMOR MARKERS
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA)
9.5.2 CA19-9 BIOMARKER TEST
9.5.3 CA 50 MARKER TEST
9.5.4 OTHERS
9.6 BIOPSY
9.7 OTHERS
10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE III
10.3 STAGE IV
10.4 STAGE II
10.5 STAGE I
10.6 STAGE 0
11 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 GERIATRIC
11.3 ADULTS
11.4 PEDIATRIC
12 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
12.1 OVERVIEW
12.2 ADENOCARCINOMA
12.3 COLORECTAL LYMPHOMA
12.4 GASTROINTESTINAL STROMAL TUMORS
12.5 CARCINOID TUMORS
12.6 OTHERS
13 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC CENTERS
13.4 CANCER RESEARCH CENTERS
13.5 AMBULATORY SURGICAL CENTERS
13.6 ACADEMIC INSTITUTES
13.7 OTHERS
14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F. HOFFMANN- LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 KONINKLIJKE PHILIPS N.V.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 THERMO FISHER SCIENTIFIC INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 ILLUMINA, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 QUEST DIAGNOSTICS INCORPORATED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BEIJING O&D BIOTECH CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIOFIRE DIAGNOSTICS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BIO-RAD LABORATORIES, INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 CANON MEDICAL SYSTEMS CORPORATION.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 FUJIFILM CORPORATION
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 GE HEALTHCARE.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 HOLOGIC, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MYRIAD GENETICS, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 NEUSOFT CORPORATION
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENT
17.22 PLEXBIO
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 QIAGEN
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SIEMENS HEALTHCARE GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 1.2.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 TIME MEDICAL HOLDING.
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA STOOL EXAMINATION IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA BIOPSY IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA STAGE III IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA STAGE IV IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA STAGE II IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA STAGE I IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA STAGE 0 IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA GERIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ADULTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA PEDIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA ADENOCARCINOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA COLORECTAL LYMPHOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA GASTROINTESTINAL STROMAL TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA CARCINOID TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA DIAGNOSTIC CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA CANCER RESEARCH CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA ACADEMIC INSTITUTES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 71 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 73 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 74 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 CANADA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 CANADA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 CANADA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 CANADA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 CANADA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 86 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 88 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 MEXICO INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 MEXICO PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 MEXICO KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 MEXICO REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 MEXICO BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 MEXICO IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 101 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 103 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT COLORECTAL CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 19 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 23 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 27 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 31 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 35 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
